$1.87
0.54% day before yesterday
Nasdaq, Aug 22, 10:04 pm CET
ISIN
US84833T1034
Symbol
SPRO

Spero Therapeutics, Inc. Stock price

$1.87
-0.54 22.41% 1M
+1.06 132.27% 6M
+0.84 81.55% YTD
+0.52 38.52% 1Y
+0.91 94.79% 3Y
-10.46 84.83% 5Y
-9.63 83.74% 10Y
-9.63 83.74% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.54%
ISIN
US84833T1034
Symbol
SPRO
Industry

Key metrics

Basic
Market capitalization
$105.2m
Enterprise Value
$74.0m
Net debt
positive
Cash
$31.2m
Shares outstanding
56.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.2 | 17.5
EV/Sales
1.5 | 12.3
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
41.7%
Return on Equity
-148.7%
ROCE
-119.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$48.6m | $6.0m
EBITDA
$-56.4m | -
EBIT
$-56.4m | $-82.1m
Net Income
$-53.6m | $-65.9m
Free Cash Flow
$-32.3m
Growth (TTM | estimate)
Revenue
-59.0% | -87.5%
EBITDA
-458.8% | -
EBIT
-462.2% | -13.3%
Net Income
-407.2% | 3.9%
Free Cash Flow
-124.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-116.0% | -
EBIT
-116.0%
Net
-110.3% | -1,095.2%
Free Cash Flow
-66.6%
More
EPS
$-1.0
FCF per Share
$-0.6
Short interest
3.0%
Employees
32
Rev per Employee
$1.5m
Show more

Is Spero Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Spero Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Spero Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
49 49
59% 59%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
6% 6%
51%
- Research and Development Expense 80 80
8% 8%
165%
-56 -56
459% 459%
-116%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -56 -56
462% 462%
-116%
Net Profit -54 -54
407% 407%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Spero Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spero Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
11 days ago
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Esther P. Rajavelu - CEO, CFO, President & Treasurer Shai Biran - Corporate Participant Timothy Keutzer - Chief Operating Officer Conference Call Participants Gautam Chukka - Evercore ISI Institutional Equities, Research Division Operator Good afternoon, and welcome to Spero ...
Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Neutral
GlobeNewsWire
19 days ago
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to repo...
More Spero Therapeutics, Inc. News

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Esther Rajavelu
Employees 32
Founded 2013
Website sperotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today